Effects of Mediterranean Diet, Curcumin, and Resveratrol on Mild-to-Moderate Active Ulcerative Colitis: A Multicenter Randomized Clinical Trial

被引:3
|
作者
Dogan, Ozge Erol [1 ,2 ]
Celik, Kezban Esen Karaca [3 ]
Bas, Murat [3 ]
Alan, Eyup Hakan [4 ]
Cagin, Yasir Furkan [5 ]
机构
[1] Acibadem Mehmet Ali Aydinlar Univ, Inst Hlth Sci, Dept Nutr & Dietet, TR-34752 Istanbul, Turkiye
[2] Ardahan Univ, Vocat Sch Hlth Serv, Dept Hlth Care Serv, TR-75002 Ardahan, Turkiye
[3] Acibadem Mehmet Ali Aydinlar Univ, Dept Nutr & Dietet, Fac Hlth Sci, TR-34752 Istanbul, Turkiye
[4] Malatya Training & Res Hosp, Dept Gastroenterol, TR-44330 Malatya, Turkiye
[5] Inonu Univ, Fac Med, Dept Gastroenterol, TR-44280 Malatya, Turkiye
关键词
ulcerative colitis; Mediterranean diet; curcumin; resveratrol; supplementation; inflammatory bowel diseases; INFLAMMATORY BOWEL DISEASES; QUALITY-OF-LIFE; DOUBLE-BLIND; WEIGHT-LOSS; METAANALYSIS; SUPPLEMENTATION; THERAPY; INDEXES; PATIENT; RISK;
D O I
10.3390/nu16101504
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
This study aimed to investigate the effects of the Mediterranean diet (MD), combined with curcumin and resveratrol supplementation, on disease activity, serum inflammatory markers, and quality of life in patients with mild-to-moderate active ulcerative colitis (UC). This study was designed as a prospective multicenter three-arm randomized controlled trial. Participants were randomized to the MD, MD + curcumin, and MD + resveratrol groups. All participants were placed on the MD for 8 weeks. The MD + curcumin group also received 1600 mg/day of curcumin supplementation, whereas the MD + resveratrol group received 500 mg/day of resveratrol supplementation for 8 weeks. Anthropometric measurements, Truelove-Witts Index, Short Form-36, Inflammatory Bowel Disease Questionnaire, Mediterranean Diet Adherence Scale (MEDAS), and laboratory tests were performed at baseline and postintervention. Within-group comparisons showed that MD, MD + curcumin, and MD + resveratrol interventions were effective in reducing disease activity and inflammation and improving quality of life in individuals with UC (p < 0.05). Between-group comparisons revealed no significant difference in all parameters except for the pain subparameter of SF-36 and the MEDAS score (p < 0.05). The MD is an effective and safe intervention to be used in clinical practice in individuals with UC.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Ulcerative Colitis; A Placebo Randomized Controlled Trial
    Sinclair, Jonathan
    Mclaughlin, Graham
    Allan, Robert
    Brooks-Warburton, Johanne
    Lawson, Charlotte
    Goh, Shan
    Desai, Terun
    Bottoms, Lindsay
    LIFE-BASEL, 2025, 15 (02):
  • [32] Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
    Travis, Simon P. L.
    Danese, Silvio
    Kupcinskas, Limas
    Alexeeva, Olga
    D'Haens, Geert
    Gibson, Peter R.
    Moro, Luigi
    Jones, Richard
    Ballard, E. David
    Masure, Johan
    Rossini, Matteo
    Sandborn, William J.
    GUT, 2014, 63 (03) : 433 - 441
  • [33] Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial
    Dignass, Axel
    Schnabel, Robert
    Romatowski, Jacek
    Pavlenko, Vladimir
    Dorofeyev, Andrey
    Derova, Jelena
    Jonaitis, Laimas
    Dilger, Karin
    Nacak, Tanju
    Greinwald, Roland
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (01) : 138 - 147
  • [34] Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis
    Shen, Hong
    Zhang, Shengsheng
    Zhao, Wenxia
    Ren, Shunping
    Ke, Xiao
    Gu, Qinghua
    Tang, Zhipeng
    Xie, Jingri
    Chen, Suning
    Chen, Yan
    Zou, Jiandong
    Zhang, Lu
    Shen, Zhaofeng
    Zheng, Kai
    Liu, Yajun
    Gu, Peiqing
    Cheng, Jiafei
    Hu, Jingyi
    Zhu, Lei
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
  • [35] Long-Term Clinical Outcomes and Factors Predictive of Relapse after 5-Aminosalicylate or Sulfasalazine Therapy in Patients with Mild-to-Moderate Ulcerative Colitis
    Lee, Hyun Jung
    Jung, Eun Suk
    Lee, Jin Ha
    Hong, Sung Pil
    Kim, Tae Il
    Kim, Won Ho
    Cheon, Jae Hee
    HEPATO-GASTROENTEROLOGY, 2012, 59 (117) : 1415 - 1420
  • [36] Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study
    Ma, Christopher
    Beilman, Candace L.
    Huang, Vivian W.
    Fedorak, Darryl K.
    Wong, Karen
    Kroeker, Karen I.
    Dieleman, Levinus A.
    Halloran, Brendan P.
    Fedorak, Richard N.
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 2016
  • [37] Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Ulcerative Colitis: A Protocol for a Placebo Randomized Controlled Trial
    Sinclair, Jonathan
    Dillon, Stephanie
    Allan, Robert
    Brooks-Warburton, Johanne
    Desai, Terun
    Lawson, Charlotte
    Bottoms, Lindsay
    METHODS AND PROTOCOLS, 2023, 6 (05)
  • [39] Feasibility of a Smartphone-Based Hearing Aid App for Mild-to-Moderate Hearing Loss: Prospective Multicenter Randomized Controlled Trial
    Jo, Sungmin
    Park, Moo Kyun
    Seo, Jae-Hyun
    Lee, Ki-eun
    Han, Jae Sang
    Lim, Ji Hyung
    Lee, Jun Ho
    Oh, Seung-Ha
    JMIR MHEALTH AND UHEALTH, 2023, 11
  • [40] Clinical evaluation of traditional Chinese medicine on mild active ulcerative colitis A multi-center, randomized, double-blind, controlled trial
    Kou, Fu-Shun
    Shi, Lei
    Li, Jun-Xiang
    Wang, Zhi-Bin
    Shi, Rui
    Mao, Tang-You
    Ke, Xiao
    Zhang, Bei-Ping
    Yang, Xiao-Jun
    Wen, Xin-Li
    Zheng, Wei-Yang
    Han, Xiao
    Ding, Pang-Hua
    Dong, Jun
    MEDICINE, 2020, 99 (35) : E21903